Drugs / AMPELOPSIN
AMPELOPSIN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05623501 | Sep 2024 → Dec 2025 overdue | alcohol-related disorders | University of Southern California | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03606694 | Oct 2019 → Dec 2022 | type 2 diabetes mellitus | University of Guadalajara | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMPELOPSIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3348861 ↗ |
| Known as | Ampeloptin | ChEMBL registry synonym — accepted as the source's own label CHEMBL3348861 ↗ |
| Known as | DHM | “Dihydromyricetin (DHM), a bioactive flavonoid from an edible plant (ampelopsis grossedentata), is reported to have multiple protective effects against chemical-induced liver injuries.” NCT05623501 ↗ |
| Known as | Dihydromyricetin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05623501 ↗ |
| Known as | Myriceline spe | ChEMBL registry synonym — accepted as the source's own label CHEMBL3348861 ↗ |
| Known as | Telocapil | ChEMBL registry synonym — accepted as the source's own label CHEMBL3348861 ↗ |
| Modality | Small molecule | — CHEMBL3348861 ↗ |
| Route | Oral | “with oral administration” NCT05623501 ↗ |